scholarly journals Associations Between the Ankle-Brachial Index and Cardiovascular and All-Cause Mortality Are Similar in Individuals Without and With Type 2 Diabetes: Nineteen-year follow-up of a population-based cohort study

Diabetes Care ◽  
2012 ◽  
Vol 35 (8) ◽  
pp. 1731-1735 ◽  
Author(s):  
N. M. J. Hanssen ◽  
M. S. Huijberts ◽  
C. G. Schalkwijk ◽  
G. Nijpels ◽  
J. M. Dekker ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cohort Study ◽  
Ankle Brachial Index ◽  
Population Based ◽  
All Cause Mortality

scholarly journals Mortality Risk in People with Type 2 Diabetes: A Large Prospective PopulationBased Cohort Study (The Ayrshire Diabetes Follow-Up Cohort (ADOC) Study)

2021 ◽  
Vol 6 (3) ◽  
Author(s):  
Collier A ◽  
Hair M ◽  
Cameron L ◽  
Ghosh S ◽  
Boyle J ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Mass Index ◽  
Cohort Study ◽  
Heart Disease ◽  
Smoking Status ◽  
Economic Status ◽  
Population Based ◽  
Socio Economic Status

Background: This study investigated the effects of age, gender, socio-economic status, smoking status, hypertension, ischaemic heart disease, Body Mass Index (BMI), Glycaemic control (HbA1c) and dyslipidaemia in type 2 diabetes in a population-based analysis.

scholarly journals Primary care experience and remission of Type 2 diabetes: a population-based prospective cohort study

2020 ◽  
Author(s):  
Hajira Dambha-Miller ◽  
Alexander Day ◽  
Ann Louise Kinmonth ◽  
Simon J Griffin
Keyword(s):  
Type 2 Diabetes ◽  
Primary Care ◽  
Weight Loss ◽  
Cohort Study ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Population Based ◽  
Care Experience

Abstract Background Remission of Type 2 diabetes is achievable through dietary change and weight loss. In the UK, lifestyle advice and referrals to weight loss programmes predominantly occur in primary care where most Type 2 diabetes is managed. Objective To quantify the association between primary care experience and remission of Type 2 diabetes over 5-year follow-up. Methods A prospective cohort study of adults with Type 2 diabetes registered to 49 general practices in the East of England, UK. Participants were followed-up for 5 years and completed the Consultation and Relational Empathy measure (CARE) on diabetes-specific primary care experiences over the first year after diagnosis of the disease. Remission at 5-year follow-up was measured with HbA1c levels. Univariable and multivariable logistic regression models were constructed to quantify the association between primary care experience and remission of diabetes. Results Of 867 participants, 30% (257) achieved remission of Type 2 diabetes at 5 years. Six hundred twenty-eight had complete data at follow-up and were included in the analysis. Participants who reported higher CARE scores in the 12 months following diagnosis were more likely to achieve remission at 5 years in multivariable models; odds ratio = 1.03 (95% confidence interval = 1.01–1.05, P = 0.01). Conclusion Primary care practitioners should pay greater attention to delivering optimal patient experiences alongside clinical management of the disease as this may contribute towards remission of Type 2 diabetes. Further work is needed to examine which aspects of the primary care experience might be optimized and how these could be operationalized.

scholarly journals Plasma Metabolites Associate with All-Cause Mortality in Individuals with Type 2 Diabetes

Metabolites ◽  
2020 ◽  
Vol 10 (8) ◽  
pp. 315
Author(s):  
Filip Ottosson ◽  
Einar Smith ◽  
Céline Fernandez ◽  
Olle Melander
Keyword(s):  
Type 2 Diabetes ◽  
Premature Mortality ◽  
Population Based ◽  
Plasma Metabolites ◽  
Increased Risk ◽  
All Cause Mortality ◽  
Prospective Cohorts ◽  
Diet And Cancer

Alterations in the human metabolome occur years before clinical manifestation of type 2 diabetes (T2DM). By contrast, there is little knowledge of how metabolite alterations in individuals with diabetes relate to risk of diabetes complications and premature mortality. Metabolite profiling was performed using liquid chromatography-mass spectrometry in 743 participants with T2DM from the population-based prospective cohorts The Malmö Diet and Cancer-Cardiovascular Cohort (MDC-CC) and The Malmö Preventive Project (MPP). During follow-up, a total of 175 new-onset cases of cardiovascular disease (CVD) and 298 deaths occurred. Cox regressions were used to relate baseline levels of plasma metabolites to incident CVD and all-cause mortality. A total of 11 metabolites were significantly (false discovery rate (fdr) <0.05) associated with all-cause mortality. Acisoga, acylcarnitine C10:3, dimethylguanidino valerate, homocitrulline, N2,N2-dimethylguanosine, 1-methyladenosine and urobilin were associated with an increased risk, while hippurate, lysine, threonine and tryptophan were associated with a decreased risk. Ten out of 11 metabolites remained significantly associated after adjustments for cardiometabolic risk factors. The associations between metabolite levels and incident CVD were not as strong as for all-cause mortality, although 11 metabolites were nominally significant (p < 0.05). Further examination of the mortality-related metabolites may shed more light on the pathophysiology linking diabetes to premature mortality.

scholarly journals Does Sitagliptin Affect the Rate of Osteoporotic Fractures in Type 2 Diabetes? Population-Based Cohort Study

2016 ◽  
Vol 101 (5) ◽  
pp. 1963-1969 ◽  
Author(s):  
Sumit R. Majumdar ◽  
Robert G. Josse ◽  
Mu Lin ◽  
Dean T. Eurich
Keyword(s):  
Type 2 Diabetes ◽  
Cohort Study ◽  
Fracture Risk ◽  
Large Population ◽  
Osteoporotic Fractures ◽  
Population Based ◽  
Increased Risk ◽  
Multivariable Analyses

Abstract Context: Type 2 diabetes and osteoporosis are both common, chronic, and increase with age, whereas type 2 diabetes is also a risk factor for major osteoporotic fractures (MOFs). However, different treatments for type 2 diabetes can affect fracture risk differently, with metaanalyses showing some agents increase risk (eg, thiazolidinediones) and some reduce risk (eg, sitagliptin). Objective: To determine the independent association between new use of sitagliptin and MOF in a large population-based cohort study. Design, Setting, and Subjects: A sitagliptin new user study design employing a nationally representative Unites States claims database of 72 738 insured patients with type 2 diabetes. We used 90-day time-varying sitagliptin exposure windows and controlled confounding by using multivariable analyses that adjusted for clinical data, comorbidities, and time-updated propensity scores. Main Outcomes: We compared the incidence of MOF (hip, clinical spine, proximal humerus, distal radius) in new users of sitagliptin vs nonusers over a median 2.2 years follow-up. Results: At baseline, the median age was 52 years, 54% were men, and median A1c was 7.5%. There were 8894 new users of sitagliptin and 63 834 nonusers with a total 181 139 person-years of follow-up. There were 741 MOF (79 hip fractures), with 53 fractures (4.8 per 1000 person-years) among new users of sitagliptin vs 688 fractures (4.0 per 1000 person-years) among nonusers (P = .3 for difference). In multivariable analyses, sitagliptin was not associated with fracture (adjusted hazard ratio 1.1, 95% confidence interval 0.8–1.4; P = .7), although insulin (P &lt; .001), sulfonylureas (P &lt; .008), and thiazolidinedione (P = .019) were each independently associated with increased fracture risk. Conclusions: Even in a young population with type 2 diabetes, osteoporotic fractures were not uncommon. New use of sitagliptin was not associated with fracture, but other commonly used second-line agents for type 2 diabetes were associated with increased risk. These data should be considered when making treatment decisions for those with type 2 diabetes at particularly high risk of fractures.

Sign in / Sign up

Export Citation Format

Share Document